Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...
The 2024 conference has 28 late-breakers plus plenty of basic and population science. More than anything, it’s a celebration.
Eli Lilly's Phase 3 study shows tirzepatide significantly cuts type 2 diabetes risk and supports 22.9% average weight loss in adults over three years.
Results from the SURMOUNT-1 trial show that weekly injections of tirzepatide could stop the progression from pre-diabetes to ...
Eli Lilly has reported comprehensive outcomes from the SURMOUNT-1 study of tirzepatide for treating pre-diabetic and obese ...
Analysts cited data from a phase one study showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone ...
In late 2023, the FDA approved Zepbound (tirzepatide), a weekly injection, for weight loss in adults. Unlike other weight-loss injections, Zepbound is the first GLP-1/GIP receptor agonist marketed ...
When I lost weight on WW, I devoted all of my time to the program and I was successful. It was when life got hard that the ...
Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes ...
As a diabetes specialist, I’ve treated thousands of patients, some in Beverly Hills and some in East Los Angeles. My Beverly Hills patients live to become healthy 80- and 90-year-olds. I can’t ...